NASDAQ$SCYX
Scynexis Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
SCYNEXIS reported financial results for the year ended December 31, 2023.
SCYNEXIS reported a net income of $67.0 million for the full year 2023, a significant turnaround from the previous year's net loss of $62.8 million. The company's cash, cash equivalents, and investments totaled $98.0 million at the end of 2023, providing a cash runway of more than two years. Key developments include the progression of SCY-247 and the exclusive license agreement with GSK for ibrexafungerp.
- SCY-247's IND-enabling activities are advancing, with Phase I initiation anticipated in the second half of 2024.
- Data analysis for the FURI study is ongoing, and top-line data from the CARES study is positive and consistent with previous results.
- Clinical study reports for FURI, CARES, and NATURE are on track for delivery to GSK in the first half of 2024, potentially triggering a $10 million milestone payment.
- SCYNEXIS ended 2023 with $98.0 million in cash, cash equivalents, and investments, projecting a cash runway of over two years.
Headline financials
Revenue & EPS history
Scynexis · Revenue · Quarterly
$5.8M
Revenue by segment
Scynexis · $22M total across 2 segments · Q4 2025
- License Agreement Revenue$20.6M+456.8%93.6%
- Product Revenue$1.4M—6.4%
Forward guidance
SCYNEXIS anticipates several key milestones in the near future, including the initiation of Phase I clinical studies for SCY-247 and the potential receipt of a $10 million development milestone payment from GSK.
Tailwinds
- Advancement of SCY-247's IND-enabling activities.
- Positive top-line data from the CARES study.
- Potential $10 million development milestone payment from GSK.
- Strong cash balance providing a runway beyond two years.
- Delivery of clinical study reports to GSK in the first half of 2024
Headwinds
- Risks inherent in regulatory and other costs in developing products.
- Potential delays in clinical study timelines.
- Uncertainties related to the commercial success of licensed products.
- Dependence on collaborations and partnerships for development and commercialization.
- Competition from other companies in the antifungal market.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2023
+12.3%
Avg return
Earnings day
+14.8%
Avg return
5 days after
+10.7%
Avg return
30 days after
53%
28 / 53 earnings
Positive
+619.7%
Q1 2026
Best reaction
-38.9%
Q1 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +619.7% | +546.3% | +353.1% | |
| Q4 2025 | +2.9% | +16.1% | +14.6% | |
| Q3 2025 | -5.6% | -4.8% | +4.0% | |
| Q2 2025 | -5.3% | -6.5% | +32.5% | |
| Q1 2025 | +28.6% | +21.9% | -5.3% | |
| Q4 2024 | -1.0% | -5.9% | +1.0% | |
| Q3 2024 | +0.0% | -3.0% | -9.8% | |
| Q2 2024 | -5.4% | -7.0% | -31.7% | |
| Q1 2024 | +1.6% | +10.6% | +20.3% | |
| Q4 2023 | +4.2% | +1.8% | +8.1% | |
| Q3 2023 | +0.3% | -5.0% | -2.1% | |
| Q2 2023 | -8.0% | -1.7% | +13.0% | |
| Q1 2023 | -3.8% | +1.0% | -4.5% | |
| Q4 2022 | +24.8% | +21.1% | +7.1% | |
| Q3 2022 | -14.7% | -12.5% | -5.4% | |
| Q2 2022 | +0.7% | -4.5% | +2.1% | |
| Q1 2022 | +10.7% | +14.4% | +4.3% | |
| Q4 2021 | -14.5% | -17.7% | -45.1% | |
| Q3 2021 | -5.9% | +20.5% | +27.7% | |
| Q2 2021 | -2.2% | -6.2% | -5.8% | |
| Q1 2021 | +11.5% | +21.1% | +5.6% | |
| Q4 2020 | +1.0% | +8.2% | -2.0% | |
| Q3 2020 | +13.3% | +15.4% | +34.0% | |
| Q2 2020 | -2.0% | -2.9% | -28.0% | |
| Q1 2020 | -0.3% | -7.3% | +1.2% | |
| Q4 2019 | -22.7% | -29.7% | +1.0% | |
| Q3 2019 | +3.5% | -1.3% | -34.9% | |
| Q2 2019 | +2.8% | +0.0% | +2.8% | |
| Q1 2019 | -2.6% | -7.8% | -24.0% | |
| Q4 2018 | +19.0% | +37.3% | +45.2% | |
| Q3 2018 | -2.3% | -8.4% | -41.2% | |
| Q2 2018 | -6.1% | -10.1% | -12.2% | |
| Q1 2018 | +8.5% | +7.6% | +52.5% | |
| Q4 2017 | +2.7% | +3.4% | -11.0% | |
| Q3 2017 | -9.3% | -9.3% | +12.9% | |
| Q2 2017 | +1.9% | -2.5% | +35.6% | |
| Q1 2017 | -38.9% | -36.2% | -37.4% | |
| Q4 2016 | +9.0% | +11.9% | -5.2% | |
| Q3 2016 | +4.5% | +18.5% | +14.3% | |
| Q2 2016 | -1.9% | +3.8% | +41.8% | |
| Q1 2016 | -4.3% | — | — | |
| Q4 2015 | +0.7% | — | — | |
| Q3 2015 | +6.9% | — | — | |
| Q2 2015 | -3.2% | — | — | |
| Q1 2015 | -4.3% | — | — | |
| Q4 2014 | +5.1% | — | — | |
| Q3 2014 | -0.8% | — | — | |
| Q3 2013 | -0.8% | — | — | |
| Q2 2013 | +7.7% | — | — | |
| Q2 2014 | +7.7% | — | — | |
| Q1 2014 | +5.7% | — | — | |
| Q4 2013 | +5.7% | — | — | |
| Q1 2013 | +5.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro